Loading
NASDAQHealthcareBiotechnology
Latest quote
$56.23
−$1.22 · -2.12%
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Previous close
$56.23
−$1.22 · -2.12%
Pre-market
$56.74
+$0.51 · +0.91%
Sep 11, 5:01 AM ET
Regular session · ET · Market data may be delayed.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Day range
Current $56.23
52-week range
Current $56.23
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
33
Moderate Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Day range
Current $56.23
52-week range
Current $56.23
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 263K USD | — | — | — | — |
| Gross profit | −263K USD | — | — | — | — |
| Research and development | 85.86M USD | 80.78M USD | 64.57M USD | 31.02M USD | 20.47M USD |
| Selling, general, and administrative | 33.8M USD | 23.78M USD | 18.96M USD | 7.77M USD | 4.29M USD |
| Operating expenses | 119.4M USD | 104.55M USD | 83.53M USD | 38.79M USD | 24.76M USD |
| Interest income | 16.01M USD | 14.89M USD | 11.97M USD | 1.13M USD | 22K USD |
| Depreciation and amortization | 263K USD | 317K USD | 297K USD | 215K USD | 115K USD |
| Operating income | −119.66M USD | −104.55M USD | −83.53M USD | −38.79M USD | −24.76M USD |
| Net income | −103.69M USD | −89.02M USD | −71.58M USD | −37.66M USD | −24.74M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$76.00
35.16% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
